525 related articles for article (PubMed ID: 18759920)
61. Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation.
Pende D; Falco M; Vitale M; Cantoni C; Vitale C; Munari E; Bertaina A; Moretta F; Del Zotto G; Pietra G; Mingari MC; Locatelli F; Moretta L
Front Immunol; 2019; 10():1179. PubMed ID: 31231370
[TBL] [Abstract][Full Text] [Related]
62. KIR-HLA receptor-ligand mismatch associated with a graft-versus-tumor effect in haploidentical stem cell transplantation for pediatric metastatic solid tumors.
Pérez-Martínez A; Leung W; Muñoz E; Iyengar R; Ramírez M; Vicario JL; Lassaletta A; Sevilla J; González-Vicent M; Madero L; Díaz-Pérez MA
Pediatr Blood Cancer; 2009 Jul; 53(1):120-4. PubMed ID: 19215002
[TBL] [Abstract][Full Text] [Related]
63. An overview of methods required to evaluate donor NK cell alloreactivity for haploidentical haemopoietic stem cell transplantation.
Velardi A
Methods Mol Biol; 2012; 882():469-76. PubMed ID: 22665250
[TBL] [Abstract][Full Text] [Related]
64. Natural killer cells--new understanding of basic biology may lead to more effective allogeneic haematopoietic stem cell transplantation.
Patil S; Schwarer T
Intern Med J; 2009 Oct; 39(10):639-47. PubMed ID: 19686544
[TBL] [Abstract][Full Text] [Related]
65. Variable interactions of recipient killer cell immunoglobulin-like receptors with self and allogenic human leukocyte antigen class I ligands may influence the outcome of solid organ transplants.
Rajalingam R
Curr Opin Organ Transplant; 2008 Aug; 13(4):430-7. PubMed ID: 18685341
[TBL] [Abstract][Full Text] [Related]
66. Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation.
Dupont B; Hsu KC
Curr Opin Immunol; 2004 Oct; 16(5):634-43. PubMed ID: 15342011
[TBL] [Abstract][Full Text] [Related]
67. The role of natural killer cells in human solid organ and tissue transplantation.
Villard J
J Innate Immun; 2011; 3(4):395-402. PubMed ID: 21411978
[TBL] [Abstract][Full Text] [Related]
68. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
[TBL] [Abstract][Full Text] [Related]
69. The history and future prospective of haplo-identical stem cell transplantation.
Handgretinger R; Lang P
Cytotherapy; 2008; 10(5):443-51. PubMed ID: 18615344
[TBL] [Abstract][Full Text] [Related]
70. Influence of killer immunoglobulin-like receptor/HLA ligand matching on achievement of T-cell complete donor chimerism in related donor nonmyeloablative allogeneic hematopoietic stem cell transplantation.
Sobecks RM; Ball EJ; Askar M; Theil KS; Rybicki LA; Thomas D; Brown S; Kalaycio M; Andresen S; Pohlman B; Dean R; Sweetenham J; Macklis R; Bernhard L; Cherni K; Copelan E; Maciejewski JP; Bolwell BJ
Bone Marrow Transplant; 2008 Apr; 41(8):709-14. PubMed ID: 18195688
[TBL] [Abstract][Full Text] [Related]
71. KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation.
Kreijveld E; van der Meer A; Tijssen HJ; Hilbrands LB; Joosten I
Transplantation; 2007 Oct; 84(8):1045-51. PubMed ID: 17989611
[TBL] [Abstract][Full Text] [Related]
72. NK cells contribute to the skin graft rejection promoted by CD4+ T cells activated through the indirect allorecognition pathway.
Ito A; Shimura H; Nitahara A; Tomiyama K; Ito M; Kanekura T; Okumura K; Yagita H; Kawai K
Int Immunol; 2008 Oct; 20(10):1343-9. PubMed ID: 18697765
[TBL] [Abstract][Full Text] [Related]
73. Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Nonn M; Herr W; Khan S; Todorova M; Link I; Thies J; Distler E; Kaltwasser M; Hoffmann J; Huber C; Hartwig UF
Transplantation; 2008 Nov; 86(10):1427-35. PubMed ID: 19034014
[TBL] [Abstract][Full Text] [Related]
74. Natural killer cell tolerance licensing and other mechanisms.
Jonsson AH; Yokoyama WM
Adv Immunol; 2009; 101():27-79. PubMed ID: 19231592
[TBL] [Abstract][Full Text] [Related]
75. Killer-cell immunoglobulin-like receptors reactivity and outcome of stem cell transplant.
Velardi A; Ruggeri L; Mancusi A
Curr Opin Hematol; 2012 Jul; 19(4):319-23. PubMed ID: 22555394
[TBL] [Abstract][Full Text] [Related]
76. High-Risk Leukemia: Past, Present, and Future Role of NK Cells.
Mavers M; Bertaina A
J Immunol Res; 2018; 2018():1586905. PubMed ID: 29850617
[TBL] [Abstract][Full Text] [Related]
77. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation.
Ruggeri L; Capanni M; Casucci M; Volpi I; Tosti A; Perruccio K; Urbani E; Negrin RS; Martelli MF; Velardi A
Blood; 1999 Jul; 94(1):333-9. PubMed ID: 10381530
[TBL] [Abstract][Full Text] [Related]
78. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction.
Marcenaro E; Cantoni C; Pesce S; Prato C; Pende D; Agaugué S; Moretta L; Moretta A
Blood; 2009 Nov; 114(19):4108-16. PubMed ID: 19749090
[TBL] [Abstract][Full Text] [Related]
79. Use of NK cell activity in cure by transplant.
Leung W
Br J Haematol; 2011 Oct; 155(1):14-29. PubMed ID: 21812770
[TBL] [Abstract][Full Text] [Related]
80. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
Guo H; Qian X
Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
